These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38066089)

  • 1. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma.
    Jagirdar K; Portuallo ME; Wei M; Wilhide M; Bravo Narula JA; Robertson BM; Alicea GM; Aguh C; Xiao M; Godok T; Fingerman D; Brown GS; Herlyn M; Elad VM; Guo X; Toska E; Zabransky DJ; Wubbenhorst B; Nathanson KL; Kwatra S; Goyal Y; Ji H; Liu Q; Rebecca VW
    Oncogene; 2024 Feb; 43(6):395-405. PubMed ID: 38066089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERK Hyperactivation Serves as a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous Melanoma.
    Rebecca V; Jagirdar K; Portuallo M; Wei M; Wilhide M; Bravo J; Robertson B; Alicea G; Aguh C; Xiao M; Godok T; Fingerman D; Brown G; Herlyn M; Guo B; Toska E; Zabransky D; Wubbenhorst B; Nathanson K; Kwatra S; Goyal Y; Ji H; Liu Q
    Res Sq; 2023 Apr; ():. PubMed ID: 37131684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer - A Clinical Review.
    Benvenuti C; Grinda T; Rassy E; Dixon-Douglas J; Ribeiro JM; Zambelli A; Santoro A; Pistilli B
    Curr Treat Options Oncol; 2024 Dec; 25(12):1517-1537. PubMed ID: 39614985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population.
    Chen BF; Tsai YF; Chao TC; Lien PJ; Lin YS; Feng CJ; Chen YJ; Cheng HF; Liu CY; Lai JI; Tseng LM; Huang CC
    Clin Exp Med; 2024 Aug; 24(1):185. PubMed ID: 39133334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials.
    Keskinkilic M; Arayici ME; Basbinar Y; Ellidokuz H; Yavuzsen T; Oztop I
    Breast; 2024 Dec; 78():103815. PubMed ID: 39413680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer.
    Mughal MJ; Zhang Y; Li Z; Zhou S; Peng C; Zhang YQ; Seto E; Shen M; Hall MD; Zhu W
    Cancer Lett; 2025 Feb; 610():217356. PubMed ID: 39603379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis.
    Buonaiuto R; Caltavituro A; Tafuro M; Longobardi A; Pavone G; De Santis P; Caputo R; De Angelis C; Del Mastro L; Puglisi F; Giuliano M; Arpino G; Pagliuca M; De Laurentiis M
    Breast; 2024 Nov; 79():103833. PubMed ID: 39579620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results.
    Wing K; Williamson E; Carpenter JR; Wise L; Schneeweiss S; Smeeth L; Quint JK; Douglas I
    Health Technol Assess; 2021 Aug; 25(51):1-70. PubMed ID: 34463610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy.
    Kaszubski J; Gagat M; Grzanka A; Wawrzyniak A; Niklińska W; Łapot M; Żuryń A
    Molecules; 2024 Nov; 29(22):. PubMed ID: 39598629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Far Posterior Approach for Rib Fracture Fixation: Surgical Technique and Tips.
    Manes TJ; DeGenova DT; Taylor BC; Patel JN
    JBJS Essent Surg Tech; 2024; 14(4):. PubMed ID: 39650795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.
    Harnan S; Kearns B; Scope A; Schmitt L; Jankovic D; Hamilton J; Srivastava T; Hill H; Ku CC; Ren S; Rothery C; Bojke L; Sculpher M; Woods B
    Health Technol Assess; 2024 Oct; 28(73):1-230. PubMed ID: 39487661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Epithelial-Mesenchymal Transition on Risk of Relapse and Outcome to Eribulin or Cyclin-Dependent Kinase Inhibitors in Metastatic Breast Cancer.
    Chan A; Gill J; Chih H; Wright SCE; Vasilevski N; Eichhorn PJA
    JCO Precis Oncol; 2024 Dec; 8():e2400274. PubMed ID: 39642326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enabling Systemic Identification and Functionality Profiling for Cdc42 Homeostatic Modulators.
    Malasala S; Azimian F; Chen YH; Twiss JL; Boykin C; Akhtar SN; Lu Q
    bioRxiv; 2024 Jan; ():. PubMed ID: 38260445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment.
    Smith EA; Belote RL; Cruz NM; Moustafa TE; Becker CA; Jiang A; Alizada S; Prokofyeva A; Chan TY; Seasor TA; Balatico M; Cortes-Sanchez E; Lum DH; Hyngstrom JR; Zeng H; Deacon DC; Grossmann AH; White RM; Zangle TA; Judson-Torres RL
    J Exp Clin Cancer Res; 2024 Dec; 43(1):317. PubMed ID: 39627834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Blog-Based Study of Autistic Adults' Experiences of Aloneness and Connection and the Interplay with Well-Being: Corpus-Based and Thematic Analyses.
    Petty S; Allen S; Pickup H; Woodier B
    Autism Adulthood; 2023 Dec; 5(4):437-449. PubMed ID: 38116056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.